Left ventricular hypertrophy in hypertension: Is the electrocardiogram enough for risk stratification?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Familial left ventricular noncompaction cardiomyopathy associated with the p.Asp461AsnOpen life sciences · 2026
   Article
2. Construction and validation of a nomogram to predict left ventricular hypertrophy in low-risk patients with hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2024
   Article

Corrections and comments

• Comment on
  Comparison of the efficiency between electrocardiogram and echocardiogram for left ventricular hypertrophy evaluation in patients with hypertension: Insight from the Korean Hypertension Cohort Study.2022

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as